Highlighting Nano1Health N1H-Cloud and LeishGen Platforms: A Successful Showcase at London Calling 24

On May 22nd and 23rd, our team, with eight years of dedicated experience, attended London Calling 24, the Oxford Nanopore Technologies User Meeting celebrating a decade of commercial nanopore sequencing. This conference, dedicated to nanopore sequencing users, allowed us to learn the newest technical advances and applications of nanopore sequencing and to share our innovations with researchers, clinicians, and industry leaders.

During the conference, our industrial PhD candidate, Marina Carrasco, presented our latest research on Leishmania drug-resistance prediction and test development in her poster "Drug-resistance Biomarkers in Leishmania infantum through Nanopore Sequencing and Structural Variants Analysis". This work, which received the "Highly Commended" distinction at the conference, is a significant step forward in our collective efforts to understand and combat leishmaniasis.

In her presentation, we showcased our drug-resistance prediction platforms, LeishGenApp and LeishGenR, developed over two years with support from the CDTI as part of the Neotec project, a research initiative aimed at developing innovative solutions for combating leishmaniasis. These platforms are designed to detect resistance to standard treatments against Leishmania infantum. LeishGenApp uses genome sequencing, advanced bioinformatics, and data visualization to identify genetic resistance biomarkers from cultured samples. In contrast, LeishGenR is a robust IVD tool for directly analyzing clinical samples.

This development was made possible through collaboration with several international partners. We established a cohort of 46 Leishmania infantum isolates, infecting dogs or humans, and whole genome sequenced them with nanopore technology, achieving an average genoma completeness of 98.4%. Through LeishGenApp, we identified resistance biomarkers for the five most common drugs against Leishmania infantum, detecting drug-resistance markers in 89% of the isolates.

In addition, our Torres Quevedo postdoctoral researcher, Joan Martí-Carreras, presented one of our key company assets, N1H cloud (https://www.nano1health.com/en/n1h-cloud/), our nanopore-only analysis web platform. This platform, designed for One Health research, integrates LeishGenApp, as well as several analysis products for WGS assembly (N1H-Assemblatron), 16S barcoding (N1H-Amplitron), and soon our Metagenomics classifier (N1H-Metagenomics).

For more information about our research and how we can address these challenges, please get in touch with us at info@nano1health.com or our website at www.nano1health.com.